Table II.
Features | CD44 expression
|
P-value | |||
---|---|---|---|---|---|
LEG (n=92)
|
HEG (n=18)
|
||||
N | (%) | N | (%) | ||
Age, years | |||||
≤70 | 79 | 85.9 | 12 | 82.7 | 0.81 |
>70 | 13 | 14.1 | 6 | 17.3 | |
Gender | |||||
Male | 64 | 69.6 | 15 | 83.3 | 0.390 |
Female | 28 | 30.4 | 3 | 16.7 | |
ECOG PS | |||||
0 | 38 | 41.3 | 11 | 61.1 | 0.194 |
≥1 | 54 | 58.7 | 7 | 38.9 | |
Tumor size, cm | |||||
≤10 | 87 | 94.6 | 16 | 88.9 | 0.321 |
>10 | 5 | 5.4 | 2 | 11.1 | |
T stage | |||||
T1 | 43 | 46.7 | 5 | 27.8 | 0.195 |
T2/3 | 49 | 53.3 | 13 | 72.2 | |
Fuhrman nuclear grade | |||||
G1 | 15 | 16.3 | 1 | 5.6 | 0.014 |
G2 | 65 | 70.7 | 10 | 55.6 | |
G3 | 10 | 10.9 | 6 | 33.3 | |
G4 | 2 | 2.2 | 1 | 5.6 | |
Recurrence | |||||
No | 84 | 91.3 | 7 | 38.9 | <0.001 |
Yes | 8 | 8.7 | 11 | 61.1 |
LEG, low-expression group; HEG, high-expression group. ECOG, Eastern Cooperative Oncology Group; PS, performance status.